Pharyngeal Electrical Stimulation for Treatment of Dysphagia in Subacute Stroke:A Randomized Controlled Trial by Bath, Philip M W et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Pharyngeal Electrical Stimulation for Treatment of Dysphagia in Subacute Stroke
Bath, Philip M W; Scutt, Polly; Love, Jo; Clavé, Pere; Cohen, David; Dziewas, Rainer;
Iversen, Helle K; Ledl, Christian; Ragab, Suzanne; Soda, Hassan; Warusevitane, Anushka;
Woisard, Virginie; Hamdy, Shaheen; Swallowing Treatment Using Pharyngeal Electrical








Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Bath, P. M. W., Scutt, P., Love, J., Clavé, P., Cohen, D., Dziewas, R., ... Swallowing Treatment Using
Pharyngeal Electrical Stimulation (STEPS) Trial Investigators (2016). Pharyngeal Electrical Stimulation for
Treatment of Dysphagia in Subacute Stroke: A Randomized Controlled Trial. Stroke, 47(6), 1562-1570 + tillæg.
https://doi.org/10.1161/STROKEAHA.115.012455
Download date: 03. Feb. 2020
1562
Acute stroke is complicated by oropharyngeal dysphagia in 50% of patients; of these, up to 40% remain dysphagic a 
year later.1 Dysphagia is complicated by aspiration, pneumonia, 
and malnutrition,2 and patients need enteral feeding through 
a nasogastric tube or percutaneous endoscopically introduced 
gastrostomy tube, which often requires long-term institutional 
care.3 Although dysphagia may be treated using several physical 
and behavioral techniques, there are no definitive treatments.4
Human swallowing has bilateral representation in the 
cerebral hemispheres with a dominant cortex (unrelated to 
handedness).5 Dysphagia often follows a stroke that affects 
the dominant swallowing cortex, which is then exacerbated 
in recurrent strokes. Swallowing is dependent on afferent 
feedback via bulbar cranial nerves innervating the phar-
ynx, and increased sensory input from the pharynx can 
drive long-term beneficial changes in the cortical control of 
Background and Purpose—Dysphagia is common after stroke, associated with increased death and dependency, and 
treatment options are limited. Pharyngeal electric stimulation (PES) is a novel treatment for poststroke dysphagia that has 
shown promise in 3 pilot randomized controlled trials.
Methods—We randomly assigned 162 patients with a recent ischemic or hemorrhagic stroke and dysphagia, defined as 
a penetration aspiration score (PAS) of ≥3 on video fluoroscopy, to PES or sham treatment given on 3 consecutive 
days. The primary outcome was swallowing safety, assessed using the PAS, at 2 weeks. Secondary outcomes included 
dysphagia severity, function, quality of life, and serious adverse events at 6 and 12 weeks.
Results—In randomized patients, the mean age was 74 years, male 58%, ischemic stroke 89%, and PAS 4.8. The mean 
treatment current was 14.8 (7.9) mA and duration 9.9 (1.2) minutes per session. On the basis of previous data, 45 patients 
(58.4%) randomized to PES seemed to receive suboptimal stimulation. The PAS at 2 weeks, adjusted for baseline, did not 
differ between the randomized groups: PES 3.7 (2.0) versus sham 3.6 (1.9), P=0.60. Similarly, the secondary outcomes 
did not differ, including clinical swallowing and functional outcome. No serious adverse device-related events occurred.
Conclusions—In patients with subacute stroke and dysphagia, PES was safe but did not improve dysphagia. Undertreatment 
of patients receiving PES may have contributed to the neutral result.
Clinical Trial Registration—URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25681641.   
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swallowing6 with functionally relevant reorganization of the 
swallowing cortex.6,7
During development of pharyngeal electric stimulation 
(PES), a study in healthy volunteers8,9 suggested that PES 
should be delivered at 5 Hz for 10 minutes with an electric 
current of threshold plus 75% of the difference between 
threshold and tolerance levels, a paradigm that produced the 
largest effect on brain excitability.8,10 Using this approach in 
patients with subacute stroke in a randomized dose-compar-
ison trial, PES reduced radiological aspiration, manifest as a 
reduction in penetration aspiration score (PAS).9 Similarly, 
PES reduced clinical dysphagia (assessed using the dysphagia 
severity rating scale [DSRS]) and length of stay in hospital 
in patients with dysphagia post stroke in a sham-controlled 
parallel-group phase II trial.9 In a further multicentre phase II 
randomized sham-controlled trial, PES was associated with 
nonsignificant tendencies to reduced clinical dysphagia and 
shorter length of stay in hospital.11 An individual patient data 
meta-analysis of these 3 trials found that PES significantly 
reduced aspiration (PAS) and dysphagia (DSRS) and was safe 
and well tolerated.12 Here, we present the results of a large, 
randomized, sham-controlled phase III trial of PES in patients 
with subacute poststroke dysphagia.
Materials and Methods
Participants
We did an international, multicenter, randomized, sham-controlled, 
patient-masked, outcome assessor–masked, parallel-group trial, as 
detailed in the online-only Data Supplement. In brief, patients with a 
recent stroke and videofluoroscopy (VFS)-confirmed dysphagia were 
randomized to 3 days of PES or sham stimulation, and the primary 
outcome was the penetration aspiration scale, assessed using VFS, at 
2 weeks after the third treatment session.
Patients were eligible for the trial if they were admitted to hospital 
with a clinical stroke syndrome because of ischemic or hemorrhagic 
stroke, were aged ≥18 years, had clinical dysphagia identified using 
bedside testing (as assessed by a nurse or speech and language thera-
pist using a local clinical assessment and confirmed by failure on the 
Toronto Bedside Swallowing Screening Test), were alert or rousable 
(score of 0 or 1 on question 1a of the National Institutes of Health Stroke 
Scale [NIHSS]), had a PAS ≥3 (see the online-only Data Supplement for 
description) of for at least 1 swallow (assessed using VFS),13 and could 
be treated within 42 days of stroke onset. The diagnosis of ischemic or 
hemorrhagic stroke was confirmed with computed tomography or mag-
netic resonance imaging performed between hospitalization and enroll-
ment and using standard imaging techniques. Key exclusion criteria 
included a history of dysphagia, dysphagia from a condition other than 
stroke, advanced dementia, implanted pacemaker or cardiac defibrilla-
tor in situ, unstable cardiopulmonary status or a condition that compro-
mised cardiac or respiratory status, distorted oropharyngeal anatomy, 
additional diagnosis of a progressive neurological disorder, receiving 
continuous oxygen treatment, or pregnant or nursing mother.
Ethics and Approvals
The study was approved by national ethics committees and competent 
authorities in each participating country, and locally at each site, and 
was adopted by the UK National Institute for Health Research Stroke 
Research Network. We obtained written informed consent from 
each patient, or proxy consent from a relative when the patient did 
not have capacity (eg, because of dysphasia and confusion), before 
enrollment and in accordance with national regulations; in Germany, 
the Bundesamt für Strahlenschutz regulatory authority did not allow 
proxy consent. The trial was run by a Trial Management Committee 
(P.M.B., S.H., C.M., and J.L.). An independent data-monitoring 
committee reviewed unmasked data every 6 months. The trial was 
registered as ISRCTN25681641.
Randomization
VFS (see below) was performed as a study procedure after consent to 
confirm the presence of dysphagia (PAS ≥3).14 Investigators entered 
baseline and follow-up data into a commercial database (Rave, 
Medidata Solutions, Inc) linked to a randomization list (Quantics 
Consulting, Ltd). The data were checked to confirm the patient’s 
eligibility, and the system then assigned a participant to treatment 
with active PES or sham PES with allocation 1:1. Allocation was by 
randomly permuted blocks (of size 6) with stratification by center 
and feeding status (presence/absence of artificial feeding) to enhance 
balance between treatment groups.
VFS
VFS was performed using local protocols at each participating site by 
a speech and language therapist or a radiologist. At each time point 
(baseline and weeks 2 and 12), each participant was given up to 6×5 
mL bolus drinks of contrast agent (Omnipaque 300 in UK, Visipaque 
270 in France, or Accupaque 300) of liquid consistency (≈40% wt/
vol). A 50 mL drink of contrast agent was then administered and 
swallows recorded.
At baseline, bolus drinks were taken until 3 were positive (ie, 
at least 1 swallow within a bolus of PAS ≥3); once achieved, fur-
ther bolus drinks were not given to reduce the risk of aspiration 
and pneumonia. Hence, between 3 and 7 boli (each inducing ≥1 
swallows) were administered. Once completed, quality-assured 
digital VFS image files for each swallow for each bolus were sent 
immediately to 1 of 2 independent adjudicators who were blinded 
to clinical information and who confirmed whether the patient ful-
filled the inclusion criteria on the basis of aspiration of radiological 
contrast. Use of digital VFS reduced the risk of image degradation 
on file transfer. Once confirmation was received, treatment could 
be started. VFS images at weeks 2 and 12 were similarly uploaded 
and assessed by 1 of 2 adjudicators who were blinded to patient 
details and randomization. Silent aspiration was defined as aspira-
tion without an attempted cough as seen on the video file, accom-
panying sound, or event monitor.
Procedures
Sterile single-patient use treatment catheters (Phagenyx, Phagenesis, 
Ltd, Manchester, UK), which contain an inner lumen for feeding, 
were inserted via the nose by trained staff. The catheter was inserted 
to an aboral depth related to the patient’s height so that the pair of ring 
treatment electrodes located on the outer surface of the catheter were 
adjacent to the pharynx.
Treatment was started once dysphagia was confirmed by VFS and 
given daily for 3 days.9 At each session, the catheter was connected to 
the controlling base station, and electric current at 5 Hz was increased 
incrementally from 1 mA to detect threshold (patient first aware 
of stimulation) and then tolerated (patient does not want current 
increased further) intensity levels in all patients. Those randomized 
to active PES were then administered this for 10 minutes at a treat-
ment current (mA) of threshold plus 75% of the difference between 
threshold and tolerance levels; this paradigm was used successfully 
in earlier studies of PES and considered to be an effective level of 
stimulation without being too near the tolerance level.12 Patients ran-
domized to sham therapy had no stimulation after establishment of 
threshold and tolerated levels. Patients, but not the treating researcher, 
were masked to treatment assignment. Treatment could be stopped if 
the patient withdrew consent, for safety reasons, or if unacceptable 
adverse events developed.
Active or sham PES treatment was given in addition to standard 
stroke care, including thrombolysis if administered at admission 
to hospital, and rehabilitation. Systematic use of antihypertensive 
agents (all patients), oral antithrombotic and lipid-lowering agents, 
and carotid endarterectomy (patients with ischemic stroke) were 
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recommended for secondary prevention as per each site’s local prac-
tice. The final diagnosis was confirmed at discharge based on clinical 
presentation and neuroimaging.
Outcomes
The primary outcome measure was radiological aspiration at 2 weeks 
assessed as the PAS using VFS.14 The timing of VFS at 2 weeks 
reflected that used in 3 pilot trials.12 As a secondary outcome, PAS 
was also measured at 12 weeks.
Other prespecified secondary outcomes at 2, 6, and 12 weeks included 
clinical dysphagia (DSRS9; see the online-only Data Supplement), 
dependency (modified Rankin Scale [mRS]15,16), activities of daily liv-
ing/disability (Barthel Index17), impairment (NIHSS18), health-related 
quality of life (European Quality of Life-5 Dimensions [EQ-5D],19 from 
which health utility status was calculated [EQ-5D-HUS]), and nutri-
tional measures (weight, mid-arm circumference, and blood albu-
min). At discharge from initial admittance to hospital, investigators 
recorded duration of stay and discharge destination (to institution or 
home).
The safety outcomes were all-cause case fatality and cause-spe-
cific case fatality; serious adverse events and serious adverse device-
related events; and cases of chest infection or pneumonia (diagnosed 
locally because the diagnosis of chest infection and pneumonia is 
poorly defined20).
A member of the central research team (S.H.), who was masked to 
treatment assignment, validated and categorized investigator-reported 
serious adverse events, including cause-specific deaths. Patients who 
did not receive their assigned treatment or who did not adhere to the 
protocol were followed up in full. The recruiting site, using a separate 
nontreating researcher who was masked to treatment allocation, did 
post-treatment follow-ups at 2, 6, and 12 weeks.
Statistical Analyses
The statistical analysis plan was published on the Phagenesis, Ltd, 
website before data lock and unblinding: http://www.phagenesis.
com/wp-content/uploads/2012/09/Statistical-Analysis-Plan-STEPS.
pdf (March 21, 2012). The trial was designed to recruit 140 patients 
so as to detect an absolute reduction in the change in PAS (mean 
of all swallows from all available boli) from baseline to 2 weeks of 
1.1 point (SD 1.8) between the treatment groups, with power 90%, 
2-sided significance 5%, and allowance for incomplete data/losses to 
follow-up in 15% of patients. After analysis of individual patient data 
from 3 pilot studies,12 the primary analysis was changed to compari-
son between the treatment groups of the mean of the worst swallow 
in each of the 3 to 7 available boli (with adjustment for the same at 
baseline, and no imputation of missing data) because this seemed to 
be more robust statistically and was felt to be clinically more relevant, 
a decision that was made before unblinding of data.
Four analysis populations were created: randomized, all those 
who were assigned to PES or sham treatment; safety, all randomized 
patients who had treatment attempted, that is, insertion of the treat-
ment catheter with or without PES/sham; efficacy, all randomized 
patients who received at least 1 episode of PES/sham treatment and 
who had the primary outcome (PAS) measured at both baseline and 
2 weeks; and per protocol, randomized patients who received all 3 
treatments and who had PAS data measured at baseline and 2 weeks.
Swallowing was analyzed as a comparison between the treatment 
groups using multiple linear regression with adjustment of the on-
treatment PAS for baseline PAS, stratification variables (site and feed-
ing status), and prognostic baseline variables (age, sex, and NIHSS). 
Secondary analyses used multiple linear regression (continuous data, 
eg, EQ-5D), ordinal logistic regression (ordered categorical data, eg, 
mRS), binary logistic regression (dichotomous data, eg, PAS ≤3, seri-
ous adverse events, and chest infection), and Kaplan–Meier and Cox 
regression models (time to event, eg, death). 95% confidence inter-
vals (CI) are presented, and P<0.05 was considered statistically sig-
nificant. Analyses were performed using SAS version 9.3. Summary 
meta-analyses based on group data from Swallowing Treatment 
Using Pharyngeal Electrical Stimulation (STEPS) and earlier trials9,11 
were produced using the Cochrane Collaboration’s Review Manager 
software (version 5.3).
Additional Information
Further information on Materials and Methods is given in the online-
only Data Supplement.
Results
Between April 2012 and September 2014, we consented 195 
patients; screened 181 patients with VFS; assigned treatment 
in 162 patients (randomized population); attempted treatment 
in 152 patients (safety population); treated (with at least 1 
session of PES or sham) 141 patients; and obtained VFS in 
126 patients at 2 weeks (primary outcome population) and 
95 patients at 12 weeks (Figure 1). The reduction in numbers 
between consent and randomization reflected patients who: 
screened negative for aspiration on VFS, could not have the 
catheter inserted, and did not have a VFS 2 weeks after treat-
ment. The 162 randomized patients were recruited from 20 
sites in 5 countries (Denmark, France, Germany, Spain, and 
United Kingdom, listed in the online-only Data Supplement); 
of these, 87 patients were assigned active PES and 75 patients 
were assigned to the sham group (Figure 1). Hundred and one 
patients (62.3%) were recruited from the United Kingdom. 
The randomized groups were well balanced at baseline (Table 
1): mean age 74 (SD 11) years, 94 (58%) were male, and 
143 (89%) patients had an ischemic stroke. The mean time 
from stroke to randomization was 13 (10) days. The Data 
Monitoring Committee reviewed the trial on 3 occasions and 
recommended that the trial should continue each time.
Adherence with assignment to active or sham PES was 
good in 141 participants who received at least 1 treatment 
session. There were no material differences at baseline in 15 
treated participants who did not have VFS at 2 weeks versus 
126 treated participants who did have VFS. No patients ran-
domized to sham received active treatment, and all patients 
with a catheter inserted and randomized to PES received at 
least 1 active treatment session. The mean treatment stimu-
lation level was 14.5 mA in those randomized to PES, with 
mean treatment duration 9.8 minutes and mean number of 
treatments 3.0 (Table I in the online-only Data Supplement). 
However, evidence of suboptimal treatment current levels 
seemed to be present: 58% of PES-treated patients had a treat-
ment level <10.2 mA (a figure chosen from earlier research12), 
identical treatment and threshold levels, or a treatment level 
less than threshold.
In the primary outcome population, the mean PAS at base-
line was 4.8 (SD 2.0) and reduced in both active PES and 
sham PES groups at 2 weeks (Table 2). When adjusted for site, 
age, NIHSS, baseline feeding status, and PAS, there was no 
difference in PAS at 2 weeks, mean difference 0.14 (95% CI, 
−0.37 to 0.64; P=0.60; Table 2 and Figure 2); the mean change 
in PAS from baseline to 2 weeks did not differ between the 
2 treatment groups: active PES −1.2 (1.8) versus sham PES 
−1.2 (1.8) and difference 0.14 (−0.37 to 0.64). Meta-analysis 
of individual patient data from earlier studies suggested that 
different approaches to statistical analysis varied in their sta-
tistical efficiency;12 in sensitivity analyses, PAS did not differ 
between the groups when assessed using different statistical 
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approaches (Table II in the online-only Data Supplement). 
When assessed in prespecified subgroups, no significant inter-
actions were present (Figure 2).
PES had no significant effects on secondary measures of 
swallowing and feeding, including radiological aspiration 
(PAS) at 12 weeks, and clinical dysphagia (DSRS) and feed-
ing route at weeks 2 and 12 (Table 3; Table II in the online-
only Data Supplement). Apparent tendencies in favor of PES 
were present at week 2 (but not at week 12) for functional 
measures of outcome (mRS and Barthel Index). Other mea-
sures did not differ between the treatment groups (Table 3; 
Table II in the online-only Data Supplement). When assessed 
in prespecified subgroups, significant interactions were 
present between clinical dysphagia (DSRS) and treatment 
assignment for age and PAS (Figure I in the online-only Data 
Supplement). The number of patients with chest infection or 
pneumonia occurring after randomization (and so possibly 
related to VFS rather than subsequent PES/sham treatment) 
did not differ between the treatment groups: PES 21, sham 
11 (P=0.19). The overall rate of serious adverse events occur-
ring by end of follow-up did not differ between the 2 groups, 
and no serious adverse device-related events occurred in 
either group (Table III in the online-only Data Supplement). 
The cumulative risk of all-cause death during follow-up did 
not differ between the group given PES and the sham treat-
ment (Figure II in the online-only Data Supplement). The 
Figure 1. Flow of patients through the trial: consented, 195; screened with VFS, 181; randomized, 162; treatment attempted, 152; treated, 
141; treated with VFS at 2 weeks, 126; all 3 treatments received with VFS at 2 weeks, 123; treated with VFS at 12 weeks, 95. AE indicates 
adverse event; CIP, clinical investigational plan; Rx, randomization; SLT, speech and language therapy; and VFS, videofluoroscopy. 
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Table 1. Baseline Characteristics in the Randomized Population by Treatment Assignment
N Randomized PES Sham
Patients 162 162 87 75
Age, y 162 74.4 (11.2) 74.0 (9.9) 74.9 (12.6)
Sex, male (%) 162 94 (58.0) 48 (55.2) 46 (61.3)
Race/ethnicity (%) 162
  Asian 15 (9.3) 9 (10.3) 6 (8.0)
  Black 4 (2.5) 0 (0.0) 4 (5.3)
  White 139 (85.8) 74 (85.1) 65 (86.7)
  Other 4 (2.5) 4 (4.6) …
Modified Rankin Scale (/6) 153 4.0 (1.1) 3.9 (1.1) 4.1 (1.2)
Barthel Index (/100) 153 28.4 (29.8) 32.4 (31.7) 23.8 (26.8)
Stroke, previous (%) 162 23 (14.2) 15 (17.2) 8 (10.7)
Visible on imaging (%) 161 42 (26.1) 25 (28.7) 17 (23.0)
Stroke type (%) 161
  Ischemic/normal 143 (88.8) 77 (89.5) 66 (88.0)
  Intracerebral hemorrhage 17 (10.6) 9 (10.5) 8 (10.7)
  Nonstroke 1 (0.6) 0 (0) 1 (1.3)
Side of CT lesion (%) 158
  Left 63 (39.9) 33 (38.4) 30 (41.7)
  Right 69 (43.7) 36 (41.9) 33 (45.8)
  No lesion 26 (16.5) 17 (19.8) 9 (12.5)
Syndrome (%) 157
  Total anterior circulation 41 (26.1) 21 (24.4) 20 (28.2)
  Partial anterior circulation 69 (43.9) 44 (51.2) 25 (35.2)
  Lacunar 46 (29.3) 21 (24.4) 25 (35.2)
  Posterior circulation 1 (0.6) 0 (0.0) 1 (1.4)
Severity, NIHSS (/42) 152 9.9 (6.4) 9.6 (6.5) 10.2 (6.2)
Dysphasia, NIHSS (%) 152 55 (36.2) 29 (35.8) 26 (36.6)
Onset to randomization (days) 162
  Mean (SD) 13.4 (9.7) 12.6 (9.5) 14.4 (10.0)
  Median (IQR) 11 (6–18) 10 (5–17) 12 (6–21)
DSRS (/12) 154 7.6 (3.8) 8.0 (3.9) 7.0 (3.5)
TOR-BSST, failed (%) 162 158 (97.5) 85 (97.7) 73 (97.3)
Feeding route (%) 162
  Oral, normal diet 10 (6.2) 5 (5.7) 5 (6.7)
  Oral, soft diet 45 (27.8) 23 (26.4) 22 (29.3)
  Nasogastric 90 (55.6) 52 (59.8) 38 (50.7)
  PEG 4 (2.5) 3 (3.4) 1 (1.3)
  Other 13 (8.0) 4 (4.6) 9 (12.0)
Weight (kg) 153 71.9 (16.4) 71.9 (15.3) 72.0 (17.6)
Body mass index (kg/m2) 148 25.2 (5.0) 25.7 (4.8) 24.7 (5.2)
Mid-arm circumference (cm) 143 28.3 (3.6) 28.2 (3.7) 28.5 (3.6)
Albumin (g/L) 144 36 (5.7) 36.4 (5.8) 35.5 (5.6)
Chest infection (%) 156 8 (5.1) 3 (3.6) 5 (6.9)
Penetration aspiration scale (/8) 162 4.7 (2.0) 4.7 (2.1) 4.7 (1.9)
  PAS >2 162 148 (91.4) 79 (90.8) 69 (92.0)
Data are number (%), median (interquartile range), or mean (SD). CT indicates computed tomography; DSRS, dysphagia 
severity rating scale; NIHSS, National Institutes of Health Stroke Scale; PAS, penetration aspiration score; PEG, percutaneous 
endoscopic gastrostomy; and TOR-BSST, Toronto Bedside Swallowing Screening Test.
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treatment equipment was rated as easy to use by investiga-
tors who operated the PES treating device; however, passing 
the catheter was rated as difficult in one third of investigators 
(Table IV in the online-only Data Supplement).
In a summary meta-analysis of results from STEPS and 
earlier trials,9,11 there was no difference in PAS between 
patients randomized to PES versus sham (Figure III in the 
online-only Data Supplement). In contrast, PES was associ-
ated with a larger reduction (ie, improvement) in DSRS than 
patients randomized to sham, mean difference −0.94 (95% CI, 
−1.85 to −0.03; P=0.04; Figure IV in the online-only Data 
Supplement).
Discussion
In patients with dysphagia post stroke, PES had no signifi-
cant effect on radiological aspiration or clinical dysphagia, 
assessed as PAS and dysphagia severity rating scale, respec-
tively. Similarly, PES had no effect on dependency (mRS), 
disability (Barthel Index), or impairment (NIHSS). No safety 
issues were identified.
The explanation for these largely neutral results remains 
unclear but many possibilities need to be examined. First, PES 
may simply not be effective for treating dysphagia after stroke; 
however, this seems unlikely in the context of a positive indi-
vidual patient data meta-analysis of earlier poststroke PES stud-
ies,9,11,12 the positive summary meta-analysis for DSRS presented 
here, and positive trials in multiple sclerosis and stroke patients 
with a tracheostomy.21,22 Second, the severity of dysphagia at 
baseline will itself determine the likely success of treatment. 
Across the field of acute stroke, it is challenging to demonstrate 
efficacy in a group of patients with mild impairment because 
many patients will regain normal function spontaneously; in 
this context, mild dysphagia is likely to resolve spontaneously. 
Importantly, the regulatory authority in 1 country (Germany) 
limited recruitment to patients who could provide consent for 
themselves, and this resulted in inclusion of patients with only 
milder stroke and aspiration, a decision that would challenge 
demonstrating efficacy for many interventions. Although the 
mean baseline PAS in STEPS (PAS=4.8) was similar to previ-
ous stroke trials of PES (4.312; Table V in the online-only Data 
Supplement), it was lower than in a positive trial in multiple 
sclerosis (PAS=6.521). Of relevance, patients randomized to 
sham in the earlier studies tended to have minimal or no over-
all improvement in PAS or DSRS, whereas sham patients in 
STEPS showed improvement (Table V in the online-only Data 
Supplement). Confounding this point is the potential relevance 
of VFS to the diagnosis of dysphagia and its severity; in particu-
lar, PAS scores were noted to be highly variable during admin-
istration of contrast boli. Additionally, VFS was not readily 
available at many sites thereby limiting recruitment. We chose 
PAS (using thin boli) as a primary outcome measure based on 
previous pilot studies which showed a significant improvement 
in this measure in the active PES arm8,9 but recognize that PAS 
alone does not capture information about swallowing efficiency 
and bolus control as might come from using thick liquid boli 
and measures of pharyngeal residue/timings.
Third, and related to the issue of severity and spontaneous 
resolution, patients who are enrolled early after stroke will 
comprise a mixed group of those with severe dysphagia and 
those with milder dysphagia that will improve without treat-
ment. However, later recruitment will enhance the propor-
tion of patients with severe (or fixed) dysphagia. In reality, 
STEPS and earlier trials each recruited patients at ≈2 weeks 
poststroke.12 Fourth, participants received variable amounts of 
active speech and language therapy, and this may have con-
founded the effect of additive PES.
Fifth, patients randomized to PES may have received sub-
therapeutic stimulation levels because mean levels were lower 
in STEPS (mean treatment 14.8 mA) than in previous positive 
Table 2. PAS at 2 Weeks in the Efficacy Population by Treatment Assignment
All (N=126) PES (N=70) Sham (N=56)
OR/MD  
(95% CI), Adjusted P Value
OR/MD  
(95% CI), Unadjusted P Value
Baseline
  PAS (/8) 4.8 (2.0) 4.8 (2.1) 4.7 (1.9) … … … …
2 wk primary outcome
  Mean of all boli (/8) 3.6 (2.0) 3.7 (2.0) 3.6 (1.9) 0.14 (−0.37 to 0.64) 0.60 0.06 (−0.62 to 0.74) 0.86
  Change from baseline −1.2 (1.8) −1.2 (1.8) −1.2 (1.8) 0.14 (−0.37 to 0.64) 0.60 0.00 (−0.62 to 0.61) 1.00
  Any PAS >3 (%) 105 (83.3) 60 (85.7) 45 (80.4) 1.22 (0.29 to 5.15) 0.79 1.47 (0.57 to 3.75) 0.42
12 wk
  Mean of all boli (/8) 3.2 (2.1) 3.3 (2.2) 3.0 (2.1) 0.29 (−0.04 to 0.99) 0.41 0.24 (−0.6 to 1.08) 0.57
  Any PAS >3 (%) 69 (72.6) 36 (70.6) 33 (75.0) 0.62 (0.20 to 1.90) 0.41 0.80 (0.32 to 1.99) 0.63
Repeated measures
  Mean (/8)* … 4.1 (2.3) 3.9 (2.3) 0.51 (−0.23 to 1.25) 0.18 0.19 (−0.67 to 1.04) 0.67
All patients had diagnostic videofluoroscopy at both baseline and 2 weeks and received at least 1 treatment session. Data are number (%), median (interquartile 
range), or mean (SD), with comparisons using unadjusted and adjusted multiple linear, ordinal logistic, or binary logistic regression. CI indicates confidence interval; MD, 
mean difference; OR, odds ratio; PAS, penetration aspiration score; and PES, pharyngeal electric stimulation.
*Includes death: PAS=9.
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trials in stroke (16.8 mA12). Using a treatment level of <10.2 
mA (mean − 1 SD in previous trials12) or treatment threshold 
level ≤0 mA, 58% of participants randomized to PES may have 
been undertreated. Importantly, the magnitude of stimulation 
has been shown previously to be associated with improvement 
in aspiration.8 Investigator concerns about the potential to 
harm patients seem to have explained this situation, although 
the study showed no evidence of harm, and PES may be deliv-
ered safely up to 50 mA (the maximum that can be delivered 
by the base station), as shown in another study in patients with 
stroke.22 And last, assessment of threshold and tolerance levels 
in patients randomized to sham PES may have amounted to an 
element of stimulation. For example, a participant randomized 
to sham but who had high threshold and tolerance currents 
Figure 2. Effect of treatment on penetration aspiration score in prespecified subgroups determined at baseline, with analysis using 
adjusted multiple linear regression. CL indicates confidence limit; DSRS, dysphagia severity rating scale; LACS, lacunar circulation syn-
drome; MD, mean difference; NIHSS, National Institutes of Health Stroke Scale; PACS, partial anterior circulation syndrome; PAS, pen-
etration aspiration score; PES, pharyngeal electric stimulation; and TACS, total anterior circulation syndrome.
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will have received a potentially therapeutic form of stimula-
tion for 10 to 20 minutes (as compared with the 30+ minutes 
that patients randomized to active treatment receive). These 
potential explanations for the STEPS results have implications 
for the design of future trials of PES (and, indeed, other device 
trials) and training of investigators.
STEPS has several strengths, including the large sample size 
relative to previous studies of PES; generalizability because of 
wide inclusion criteria with both ischemic and hemorrhagic 
stroke, cortical, lacunar, and posterior syndromes, and a wide 
time window; recruitment from multiple countries in Europe; 
central concealment of treatment assignment; prospective 
collection of multiple aspiration, dysphagia, functional, and 
safety outcomes; and quality care in stroke units.
However, several limitations are also present. First, 195 
patients were consented, 162 patients randomized but only 
126 received at least 1 treatment session and had both a base-
line and on-treatment PAS. Several factors explain this drop-
out, including withdrawal of consent and failure of insertion 
of the treatment catheter (Figure 1). A protocol amendment 
required that the treatment catheter had to be inserted before, 
and not after, randomization to reduce losses of patients who 
were randomized but could not be treated. Second, PES was 
delivered in 141 patients but 15 could not have VFS per-
formed at both baseline and week 2 thereby excluding them 
from the primary analysis. Third, PES was given in a single-
blind design with the patient but not treating person masked 
to stimulation. Some patients receiving active PES may have 
been aware of stimulation, whereas patients randomized to 
sham PES may have been aware of stimulation during thresh-
old testing and possibly noticed that this was absent during the 
treatment sessions. Nevertheless, clinical outcomes measured 
at 2, 6, and 12 weeks were assessed by trained staff who were 
masked to treatment assignment and who were not involved in 
hospital care of enrolled patients. Furthermore, VFS images 
were adjudicated by radiologists or speech therapists who 
were similarly masked to randomized group.
In conclusion, we found that PES did not reduce radiologi-
cal aspiration or clinical dysphagia. This result differs from a 
positive meta-analysis of previous small trials of PES in post-
stroke dysphagia12 and may result from several factors, includ-
ing enrollment of patients with mild dysphagia, potential 
undertreatment with PES, and possible active stimulation of 
control patients. In view of this discrepancy, and the potential 
risk of overestimating treatment effect from smaller studies, 
further studies are planned in stroke patients with severe dys-
phagia or those requiring intensive care including ventilation.
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Table 3. Clinical and Safety Outcomes by Treatment Assignment in Patients Who Received At Least 1 Active or Sham Treatment 
and Who Had Outcome Measured






  DSRS (/12)* 133 5.1 (3.8) 5.2 (4.1) 4.9 (3.6) 0.31 (−0.56 to 1.18) 0.49 0.23 (−1.07 to 1.54) 0.72
  NIHSS (/42)* 134 9.6 (7.2) 9.0 (7.4) 10.2 (7.1) −0.05 (−1.42 to 1.32) 0.94 −1.19 (−3.64 to 1.26) 0.34
  mRS (/6)* 134 3.9 (1.1) 3.7 (1.2) 4.1 (1.0) 0.53 (0.23 to 1.22) 0.14 0.49 (0.26 to 0.92) 0.028
  BI (/100)* 134 36.2 (34.9) 41.3 (37.2) 29.8 (31.0) 1.57 (−3.60 to 6.73) 0.55 11.45 (−0.22 to 23.13) 0.055
  Death (%) 141 2 (1.4) 1 (1.3) 1 (1.6) … … 0.81 (0.05 to 13.13) 0.88
12 wk
  DSRS (/12)* 124 4.2 (5.1) 4.4 (5.2) 3.9 (5.1) 1.01 (−0.44 to 2.46) 0.17 0.58 (−1.23 to 2.39) 0.53
  EQ-5D as HUS (/1)* 113 0.02 (0.40) 0.08 (0.41) −0.04 (0.39) 0.13 (0.00 to 0.27) 0.054 0.12 (−0.03 to 0.27) 0.11
  EQ-VAS* 105 50.3 (30.7) 51.6 (30.1) 48.6 (31.7) −4.17 (−15.22 to 6.88) 0.46 3.03 (−8.70 to 14.76) 0.61
Disposition (%) 141 0.66 (0.30 to 1.49) 0.32 0.63 (0.31 to 1.26) 0.19
  Home 30 (21.3) 20 (25.6) 10 (15.9) … … … …
  Institution 93 (66.0) 49 (62.8) 44 (69.8) … … … …
  Died 18 (12.8) 9 (11.5) 9 (14.3) … … … …
Time to event
  Discharge (days) 141 28.2 (22.8) 27.7 (22.7) 28.7 (23.0) −0.33 (−7.79 to 7.12) 0.93 −0.97 (−9.72 to 7.78) 0.83
  Death (%) 141 18 (12.8) 9 (11.5) 9 (14.3) 1.11 (0.34 to 3.59) 0.86 0.79 (0.32 to 2.00) 0.62
BI indicates Barthel Index; DSRS, dysphagia severity rating scale; EQ-5D, European Quality of Life-5 Dimensions; EQ-VAS, European Quality of Life Visual Analogue 
Scale; HR, hazard ratio; HUS, health utility status; MD, mean difference; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; 
and PES, pharyngeal electric stimulation.
*Includes death: NIHSS=43, DSRS=13, mRS=6, BI=−5, and HUS=0.
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Training of Investigators 
All STEPS investigators were trained in the protocol, Good Clinical Practice, and use of 
the National Institutes of Health Stroke Scale, modified Rankin Scale (mRS) and 
Barthel Index. Investigators who delivered PES were trained in the technique.  
 
Schedule for Monitoring of Sites and Data Integrity 
Site monitoring was performed by trained Clinical research Associates who worked for 
Phagenesis Ltd or a delegated organisation. Their aim was to ensure quality control 
for the delivery of the protocol, collection of data and adherence with national 
regulations and ethics. Each recruiting site had a start-up visit for training, a 
monitoring visit after recruitment of the first patient, and a close-down visit; further 
visits were performed as deemed necessary by the Company. Monitoring visits 
confirmed the presence of the participant and their consent, eligibility criteria, 100% 
of data, and reporting of serious adverse events. 
 
Central statistical monitoring of the data was performed according to Buyse et al 1 
prior to locking of the data. Checks included logic and range checks, and digit 
preference. The monitoring procedures were compliant with the requirements of the 
sponsor, the national ethics committees and regulatory authorities in the participating 
countries, and fulfilled Good Clinical Practice requirements. 
 
Sample Size Considerations 
The primary endpoint for the study was change in mean penetration-aspiration scores  
(PAS) on the videofluoroscopy protocol, 2 weeks after treatment. The sample size was 
based on data gained from a phase II sham-controlled study.2 In this study, the mean 
values of the change in mean PAS in the two randomised groups of sizes 16 and 12 
were -1.4 and -0.1, giving an observed treatment effect of 1.3.The standard 
deviations in each group were 1.9 and 1.5 respectively. The distributions of values in 
each group were approximately normal, with standard deviation of 1.8.   
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Sixty patients in each group would provide 90% power to detect a difference of 
approximately 1.1 in the change in mean PAS, based on comparison of change in 
mean PAS between the two groups using a 2 sided t test, with alpha = 5%. The 
investigation was expected to provide higher power than this because the primary 
endpoint was adjusted for severity at baseline. To account for the loss of information 
caused by the potential for less than six swallows being available for every patient, 
and to account for patients dropping out before the two-week assessment, the sample 
size was increased by approximately 30%. 
 
Therefore, 160 patients should be randomised in a 1:1 ratio between the treatment 
groups, this allowing for a one-in-six attrition rate at 2 weeks. 
 
Independent Data Monitoring Committee (IDMC) 
The IDMC was responsible for safeguarding the interests of trial patients, assessing 
the safety and efficacy of the intervention during the trial, assessing data integrity, 
and for monitoring the overall conduct of the trial. The IDMC modus operandi was 
defined in a charter. The IDMC reviewed the recruitment of patients, and assessed 
safety and efficacy measures by treatment group. The trial was reviewed on three 
occasions during the trial’s recruitment period. The DMC was charged with informing 
the Trial Steering Committee if, at any time, the data showed evidence beyond 
reasonable doubt of a difference between the randomised groups in the primary 
outcome or for death. They also considered these data in the light of external 
information such as results from completed trials. One formal interim analysis was 
performed after 60 participants had been enrolled and completed the 2-week 
assessments. However, the DMC could perform statistical comparisons as they 
deemed necessary, with stopping criteria based on the Haybittle-Peto stopping rule 
(i.e. a difference of 3 standard errors is considered as clear evidence of a treatment 
effect). The study was not terminated early. 
 
Inclusion and Exclusion Criteria 
Screening Inclusion Criteria 
 Subject is over 18 years of age 
 Subject is suspected of having dysphagia 
 Subject is able to comply with videofluoroscopy protocol 
 Subject diagnosed with stroke, whether anterior or posterior circulation 
 Subject has no previous history of dysphagia 
 Subjects who are able to give voluntary, written informed consent to participate in 
the clinical investigation and from whom consent has been obtained/ or a 
consultee has consented on the subjects behalf in line with nationally agreed 
guidelines concerning adults unable to consent for themselves. 
 Subject is not currently participating in any other interventional clinical study 
 Subject is able to comply with CIP requirements  
 Subject scores 0 or 1 on questions 1a of NIHSS 
 
Randomisation Inclusion Criteria (post consent) 
 Subject has confirmed dysphagia (PAS of 3 or more on VFS screening protocol) 
 
Exclusion Criteria 
 Subject stroke event was more than 42 days ago 
 Subject is pregnant or a nursing mother 
 Subject, in the opinion of the investigator, has advanced dementia  
 Subject fitted with a pacemaker or implantable cardiac defibrillator 
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 Subject has unstable cardiopulmonary status (e.g. severe emphysema, heart 
failure) 
 Subject has distorted oropharyngeal anatomy (e.g., pharyngeal pouch) 
 Subject is dysphagic from conditions other than stroke 
 Subject has been diagnosed with a progressive neurological disorder (e.g. 
Parkinson’s disease, Multiple Sclerosis) 
 Subject has a chronic medical condition that compromises cardiac or respiratory 
status (e.g. severe emphysema or heart failure that may render the insertion of 
the throat unsafe) 
 Subject is receiving continuous oxygen treatment or the equipment for this is in 
place. 
 
Patients in intensive therapy unit, whether intubated or not, were not included since 
many would require oxygen treatment. 
 
Procedure for Videofluoroscopy (VFS, modified barium swallow) 
VFS was performed by a trained and qualified speech & language therapist or 
radiologist; they had to comply with the STEPS VFS protocol and ‘stop’ criteria. A 
common VFS protocol was used across all participating sites. Strict adherence is 
required to this VFS protocol and the criteria to ‘stop’ the procedure as defined below. 
 
Preparation 
 The subject must remain nil by mouth for 60 minutes prior to the research VFS. 
 The person delivering treatment/sham must not be present during the VFS. 
 Capture a ‘test frame’ using the x-ray equipment to ensure all data will be 
captured. 
 Ensure VFS study data is anonymised. 
 Ensure use of lead numbers or annotation throughout the VFS to identify each trial 
clearly to the independent VFS analysers. 
 Ensure use of the suprahyoid marker throughout the VFS procedure. 
 Ensure the full swallow is recorded in a lateral view using continuous/25 or 30 
frames per second screening, throughout. 
 Ensure correct positioning of the subject throughout i.e. seat upright with a neutral 
head position. 
 Ensure no use of swallowing strategies throughout e.g. head turns. 
 
Specified Contrast Media  
 The low osmolarity contrast media solution specified by Phagenesis will be used as 
the radiopaque contrast media during the STEPS VFS procedure.  
 All volumes of contrast media will be measured accurately using a syringe. 
 
VFS Protocol (see also appendix M): 
 6 trials of 5ml contrast media will be given to the subject from a small green 
Kapitex cup. 
 Subjects will be asked to pour all of the contrast media into their mouth and then 
asked to swallow.  
 50ml contrast media will then be given in a ‘normal’ beaker and the subject asked 
to drink this sequentially. 
 
Criteria to Stop the STEPS VFS Protocol: 
Stop the VFS procedure immediately if any of the following occur: 
Stage 1 (5ml trials) 
 A PAS of 7 or 8 on 3 consecutive bolus trials.  
Stage 2 (50ml trial) 
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 PAS score of 7 or 8 on 3 consecutive swallows. 
 Initial occurrence of aspiration of more than 50% of the total bolus. 
 
A ‘Stop’ may also be applied if 3 bolus trials have been complete and in the opinion of 
the staff conducting the VFS, the subject is unusually or unreasonably distressed, or if 
the subject becomes too unwell to continue. 
 
A ‘Stop’ will NOT exclude the subject from the study. 
 
VFS staff are asked to carry out the following actions in the event of the use of the 
stop criteria and/or significant aspiration.  
 Prompt the subject to cough 
 Prompt the subject to cough and swallow 
 Refer the subject for chest physiotherapy as per local practice 
 Arrange for the subject to be monitored over the next 24 hours as per local 
practice 
 
The VFS images will be analysed off line by an independent panel of specialist SALTs 
who will respond with confirmation of the need for randomisation within 24 hours of 





Penetration aspiration scale 3 
 
Score Description on videofluoroscopy 
1 Material does not enter airway 
2 Material enters airway.  
Remains above vocal cords & is ejected from airway 
3 Material is above vocal cords & is not ejected from airway 
4 Material enters airway, contacts vocal cords & ejected from airway 
5 Material contacts the vocal cords & is not ejected from airway 
6 Material passes below the vocal cords & is ejected into larynx or out of airway 
7 Material passes below the vocal cords & is not ejected from the trachea 
despite effort 
8 Material enters airway, passes below the vocal cords & no effort is made to 
eject the material 
 
 
Dysphagia severity rating scale (DSRS) 2 














4 No oral fluids 4 Non oral feeding 4 No oral feeding 
3 Pudding 
consistency 




2 Soft, moist diet 2 Feeding by third party 
(untrained) 
CONFIDENTIAL 14/03/2016 
 Page 7 of 19 
1 Syrup consistency 1 Selected 
textures 
1 Eating with 
supervision 




Since a treatment could, in principle, be associated both with improved outcome and 
death, a sensitivity analysis was performed with death assigned a score one worse 
than the worst possible PAS (death = 9) and DSRS (13) scores; this is analogous to 
the mRS and EQ-5D-HUS which both include death in their scores (6 and 0 
respectively). 
 
Role of the funding source 
The trial was overseen by the Chief Investigator (PB), PES Inventor (SH), and Trial 
Manager (JL), and run by the Trial Management Committee (PMB, SH, CM, JL), this 
including senior representatives of the funding and sponsoring company, Phagenesis 
Ltd (CM, JL). Sites received regular monitoring with 100% data verification. Data were 
collected using a commercial database (Rave, Medidata Solutions Inc.). Analyses were 
performed by PS at the University of Nottingham (PS). Interpretation and report 
writing were performed by the Trial Management Committee and National 
Coordinating Investigators. The corresponding author and another author (statistician 
PS) had full access to all the data in the study; additionally, the corresponding author 
had final responsibility for the decision to submit for publication, and is the guarantor 
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Amendments to clinical investigation 
 




Not actively used by sites – see amendment 1 France 
UK 
1: 30/1/2012  At request of UK REC - to include statement that 
clinical decision would take precedent 
 Clarify what will happen to data after 15 years 
France 
UK 
2: 19/9/2012 Non-substantial amendment: 
 Amendment to statement of conformity as now CE 
marked device. 
 Addition to the secondary objectives  
 Increased length of investigation to 18 months 
 Removed minimum and maximum site recruitment 
numbers 
 Increase in the number of sites  
 Clarification on treatment of patients according to local 
best clinical practice 
 Clarification of wording for VFS procedure  
Substantial amendment: 
 Addition to the secondary endpoints  
 Amendment to consent process at investigational sites 
in Germany  
 Addition of code-break procedure  






3: 6/6/2013 Non-substantial amendment: 
 Increased length of investigation 
 Increased number if investigation sites 
 Informed consent in non-UK sites to follow local 






4: 21/1/2014 Non-substantial amendment: 
 Increased length of investigation 
 Increased number of subjects from 140 to 160 
 Clarify target population 

















Supplementary Table I. Treatment dose and tolerance in 141 participants who 
received at least one treatment session. Treatment level is that actually received by 
patients randomised to pharyngeal electrical stimulation, or what patients randomised 
to sham would have received if actively treated. 
 
 All PES Sham 
Patients 141 78 63 
Number of treatments 414 233 181 
No. of treatments per patient 2.9 3.0 2.9 
Threshold level (mA) 9.5 (6.2) 8.9 (5.1) 10.3 (7.4) 
   Range 1, 47 1, 30 1, 47 
Tolerance level (mA) 16.9 (9.2) 16.7 (8.9) 17.3 (9.7) 
   Range 3, 50 4, 50 3, 50 
Treatment level (mA) 14.8 (7.9) 14.5 (7.5) 15.1 (8.3) 
   Range 2, 50 2, 45 2, 50 
Treatment – threshold (mA) 5.3 (5.3) 5.6 (5.6) 4.9 (5.0) 
   Range -17, 27 -2, 27 -17, 26 
Duration (minutes) 9.9 (1.2) 9.8 (1.4) 10.0 (0.7) 
   Range 0, 10 0, 10 0.2, 10 
Undertreated (%) † 85 (60.7) 45 (58.4) 40 (63.5) 
 
† Under-treatment is defined as patients with treatment <7.3 mA (mean - 1 standard 
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Supplementary Table II. Penetration aspiration score (PAS), clinical and safety outcomes by treatment assignment (intention-
to-treat) in patients who received at least one active or sham treatment and who had outcome measured. Data are number (%), 
median [interquartile range], or mean (standard deviation). Comparisons using multiple linear regression, ordinal logistic 
regression, Cox regression or binary logistic regression. Analyses were adjusted for site, age, NIHSS, feeding status, baseline PAS 
and baseline value; or unadjusted. 
 




PAS sensitivity analyses         
Mean of all boli (/9) †  126 3.7 (2.1) 3.7 (2.1) 3.7 (2.0) 0.24 (-0.32, 0.79) 0.40 0.04 (-0.67, 0.75) 0.91 
Change ‡ 123 -1.1 (1.8) -1.2 (1.8) -1.1 (1.8) 0.05 (-0.45, 0.54) 0.86 -0.05 (-0.67, 0.58) 0.89 
Mean of all swallows 
(/8) 
126 3.2 (1.8) 3.1 (1.8) 3.2 (1.8) 0.08 (-0.35, 0.50) 0.73 -0.07 (-0.70, 0.55) 0.82 
Mean number of 
swallows 
126 16.2 (8.7) 16.4 (9.9) 16.0 (7.0) -0.23 (-2.66, 
2.21) 
0.86 0.43 (-2.62, 3.47) 0.78 
Mean of first 3 boli (/8) 126 3.1 (2.2) 3.1 (2.2) 3.1 (2.2) 0.32 (-0.29, 0.92) 0.31 0.03 (-0.74, 0.79) 0.95 








0.56 2.06 (-11.66, 
15.78) 
0.77 
Worst score (/8) 126 8 [5, 8] 8 [6, 8] 8 [4.5, 8] 1.99 (0.83, 4.78) 0.12 1.68 (0.84, 3.35) 0.14 
2 weeks         
TOR-BSST, failed (%) 127 113 (89.0) 62 (88.6) 51 (89.5) 0.67 (0.08, 5.39) 0.71 0.91 (0.30, 2.80) 0.87 
Feeding (%) 132    2.07 (0.97, 4.39) 0.059 1.42 (0.77, 2.63) 0.27 
  Oral, normal food  27 (20.5) 17 (23.3) 10 (16.9)     
  Oral, soft diet  44 (33.3) 16 (21.9) 28 (47.5)     
  Nasogastric tube  31 (23.5) 21 (28.8) 10 (16.9)     
  PEG  11 (8.3) 7 (9.6) 4 (6.8)     
  Other  19 (14.4) 12 (16.4) 7 (11.9)     






0.49 (-0.72, 1.69) 0.43 -0.34 (-5.63, 4.94) 0.90 
BMI (kg/m2) 127 25.0 (4.8) 25.4 (4.4) 24.4 (5.1) 0.23 (-0.20, 0.66) 0.29 1.00 (-0.64, 2.65) 0.23 
MAC (m) 129 28.4 (4.2) 28.3 (3.7) 28.5 (4.8) 0.20 (-0.72, 1.11) 0.68 -0.22 (-1.66, 1.22) 0.77 
Albumin (g/l) 105 36.8 (5.3) 37.0  (5.7) 36.6 (4.8) -0.16 (-1.39, 
1.08) 
0.80 0.37 (-1.70, 2.44) 0.72 
12 weeks         
TOR-BSST, failed (%) 103 75 (72.8) 42 (72.4) 33 (73.3) 0.88 (0.17, 4.41) 0.87 0.95 (0.40, 2.29) 0.92 
HADS (/42) 92 11.5 (7.4) 11.0 (6.7) 12.1 (8.2) 1.80 (-0.97, 4.58) 0.20 -1.07 (-4.07, 1.93) 0.49 
Weight (kg) 101 73 (14.9) 72.1 74.1 0.56 (-1.02, 2.14) 0.49 -1.97 (-7.80, 3.85) 0.51 
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(14.3) (15.8) 
BMI (kg/m2) 98 25.5 (4.6) 25.6 (4.2) 25.4 (5.0) 0.37 (-0.19, 0.94) 0.20 0.25 (-1.56, 2.06) 0.79 
MAC (m) 104 28.3 (3.6) 27.9 (3.5) 28.7 (3.7) -0.05 (-0.83, 
0.72) 
0.89 -0.79 (-2.18, 0.60) 0.27 
Albumin (g/l) 62 41.4 (5.2) 41.7 (4.6) 41.1 (6.0) -0.28 (-1.83, 
1.27) 
0.73 0.63 (-1.96, 3.23) 0.63 
Disposition (%) 141    0.66 (0.30, 1.49) 0.32 0.63 (0.31, 1.26) 0.19 
  Home  30 (21.3) 20 (25.6) 10 (15.9)     
  Institution  93 (66.0) 49 (62.8) 44 (69.8)     
  Died  18 (12.8) 9 (11.5) 9 (14.3)     
† Includes death: PAS=9; ‡ All treatments received (N=123) 
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Supplementary Table III. Participants in the safety population (N=152) with one or 
more serious adverse events (SAE) up to 12 weeks; no serious adverse device effects 
(SADE) occurred. Data are number (%) for total and fatal events. Comparison by 
unadjusted binary logistic regression. 
 
  Any    Fatal   
 All PES Sham P All PES Sham p 
Patients 152 85 67  152 85 67  
Cardiac 9 (5.9) 6 (7.1) 3 (4.5) 0.73 4 (2.6) 2 (2.4) 2 (3.0) 1.00 
Gastrointestinal 2 (1.3) 2 (2.4) 0 (0) 0.50 0 (0) 0 (0)  0 (0) - 
General 3 (2.0) 0 (0) 3 (4.5) 0.083 3 (2.0) 0 (0) 3 (4.5) 0.083 
Hepatobiliary 1 (0.7) 1 (1.2) 0 (0) 1.00 0 (0) 0 (0) 0 (0) - 
Infections 11 (7.2) 6 (7.1) 5 (7.5) 1.00 4 (2.6) 2 (2.4) 2 (3.0) 1.00 
Investigations 1 (0.7) 1 (1.2) 0 (0) 1.00 0 (0) 0 (0) 0 (0) - 
Neoplasms 1 (0.7) 1 (1.2) 0 (0) 1.00 1 (0.7) 1 (1.2) 0 (0) 1.00 
Nervous system 8 (5.3) 4 (4.7) 4 (6.0) 0.73 4 (2.6) 3 (3.5) 1 (1.5) 0.63 
Renal/urinary 2 (1.3) 1 (1.2) 1 (1.5) 1.00 0 (0) 0 (0) 0 (0) - 
Respiratory 8 (5.3) 5 (5.9) 3 (4.5) 1.00 2 (1.3) 1 (1.2) 1 (1.5) 1.00 
Surgical/medical 2 (1.3) 2 (2.4) 0 (0) 0.50 0 (0) 0 (0) 0 (0) - 













Total SADEs 0 (0) 0 (0) 0 (0)  0 (0) 0 (0) 0 (0)  
By 2 weeks, SAE rates were: Total 13 (9.2%), PES 7 (9.0%), Sham 6 (9.5%) 
(2p=0.91) 
No SAEs were recorded as probable or possibly related to treatment 
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Supplementary Table IV. Treatment operator assessment of ease of use of device 




Provision of treatment 3 (2.2) 
Meet infection control guidelines 0 (0) 
Placement of catheter 10 (7.5) 
Passing catheter (as NGT) 44 (33.1) 
Secure catheter 19 (14.3) 
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Supplementary Table V. Penetration aspiration score (PAS) and dysphagia severity 
rating scale (DSRS) before and after treatment in the active and sham groups in four 
trials of pharyngeal electrical stimulation. Patients with both baseline and 2 week 
mean PAS are included. Data are unadjusted PAS and DSRS mean scores or 
differences. 
 
Group Timing  PAS    DSRS   













Active Before 4.8 4.6 4.5 4.8 ND 6.4 7.8 7.7 
 After 3.7 3.2 2.6 3.6  ND 2.5 4.4 5.0 
 ∆ -1.0 -1.4 -1.9 -1.1  ND -3.9 -3.4 -2.7 
Sham Before 4.3 3.9 3.9 4.7 ND 5.6 6.8 6.8 
 After 4.8 3.8 4.3 3.6 ND 4.8 5.0 4.8 
 ∆ +0.5 -0.1 +0.4 -1.1 ND -0.8 -1.8 -2 
Active-
sham 
∆ -1.5 -1.3 -2.3 0 ND -3.0 -1.5 -0.6 
 p 0.017 0.061 0.22 1.00 ND 0.11 0.11 0.25 
 










Supplementary Figure I. Effect of treatment on dysphagia severity rating scale in 
131 patients at 2 weeks in pre-specified subgroups determined at baseline. Analysed 
with multiple linear regression adjusted for baseline PAS, stratification variables (site, 
feeding status) and prognostic baseline variables (age, baseline PAS, NIHSS). 
  
The black squares represent point estimates for the mean difference, and the 
horizontal lines represent 95% confidence intervals. The rectangle incorporates the 
point estimate and the 95% confidence intervals of the overall effects within 
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Supplementary Figure II. Survival of patients randomised to pharyngeal electrical 
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Supplementary Figure III. Meta-analysis of the effect of pharyngeal electrical 
stimulation (PES) on radiological aspiration at two weeks, as assessed using the 
penetration aspiration score (PAS). Three previous trials and the present trial are 
included. Data are mean change in PAS, with 95% confidence intervals, using a 
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Supplementary Figure IV. Meta-analysis of the effect of pharyngeal electrical 
stimulation (PES) on clinical dysphagia at two weeks, as assessed using the dysphagia 
severity rating scale (DSRS). Two previous trials and the present trial are included. 
Data are mean change in DSRS from baseline, with 95% confidence intervals, using a 
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过程中，一项以健康受试者为对象 8,9 的研究表明，PES 方法的实施应
采用 5 Hz 频率、时长为 10 min、电流为阈电流值加阈电流值与耐受
水平差值的 75% 的电流值，耐受值是对脑兴奋性有最大影响的数值 8,10。
在一项随机剂量对照试验中，给予亚急性卒中患者 PES 治疗，PES 减
少了放射性误吸 , 表现为误吸评分（Penetration Aspiration Score，
PAS）值的下降 9。同样，在空白对照平行组Ⅱ期试验中，卒中后吞咽
障碍的患者给予 PES 治疗，也降低了临床吞咽障碍 [ 应用吞咽障碍严
背景和目的：卒中后吞咽障碍很常见，与死亡及照料依赖的增加相关，而治疗方法有限。咽部电刺激（pharyngeal electric stimulation，
PES）是一种新的治疗卒中后吞咽障碍的方法，这种方法经过 3 项试验性的随机对照试验，显示出了良好的应用前景。
方法：将 162 例近期患有缺血性或出血性卒中并伴有吞咽障碍的患者 [ 视频荧光透视下的误吸评分（Penetration Aspiration Score，
PAS）≥ 3）] 随机入组到 PES 治疗组或假治疗组，连续治疗 3 d。主要观察指标是吞咽安全性评估，于 2 周时采用 PAS 评分进行评估。次要观
察指标包括吞咽障碍严重程度、吞咽功能、生活质量和严重不良事件，于 6 周和 12 周时进行评估。
结果：在随机分配的患者中，平均年龄 74 岁，男性占 58%，缺血性卒中占 89%，PAS 值为 4.8。治疗中使用的平均电流是 14.8（7.9）
mA, 持续时间为每阶段 9.9（1.2）min。在之前获得数据的基础上，随机分配到 PES 治疗组的患者中的 45 例（58.4%）似乎并未接受最适刺激量。
2 周时的已校正基线的 PAS 值在随机分配的两组中差异无显著性：PES 治疗组 3.7（2.0）, 假治疗组 3.6（1.9），P=0.60。同样，次要观察指标
差异亦无显著性，包括临床吞咽和功能的结局。无严重的仪器设备相关的不良事件发生。
结论：对于亚急性卒中伴有吞咽障碍的患者，PES 治疗方法是安全的，但并不能改善吞咽障碍。患者接受 PES 治疗量不足可能导致了这种
中性结果。
关键词：吞咽障碍；咽部电刺激；随机对照试验；卒中
重程度评定量表（Dysphagia Severity Rating Scale，DSRS）进行
评估 ] 和住院时间 9。在一个远期的多中心Ⅱ期随机空白对照试验中，
PES 方法对于减少临床吞咽障碍症状和减少住院时间并没有明显的作









定的吞咽障碍患者，随机被分配到 PES 治疗组或假治疗组，治疗 3 d。










       接受所有分配到的治疗（n=74）
       接受某些分配到的治疗（n=4）
              退出-CIP依从性（n=1）
              没有给出原因（n=2）
              健康状况恶化（n=1）
       未接受分配到的治疗（n=9）
              无法耐受或无法插入导管（n=3）
              退出授权同意（n=5）
              没有给出原因（n=1）
分配到假PES治疗组（n=75）
       接受所有分配到的治疗（n=59）
       接受某些分配到的治疗（n=4）
              没有给出原因（n=1）
              退出授权同意（n=1）
              无法通过替代导管（n=1）
              患者有法定代理人（n=1）
       没有接受分配到的治疗（n=12）
              无法耐受或无法通过导管（n=4）
              对研究过程依从性差（n=1）
              退出-负性事件牙痛（n=1）
              退出授权同意（n=6）
可获取的初级终点数据（n=70）
       无VFS数据（n=17）
              未治疗（n=9）
              没有给出原因（n=1）
              退出授权同意（n=1）
              研究过程中依从性差（n=1）
              死亡（n=1）
              不耐受VFS（n=2）
              VFS影像无法读取（n=1）
              采取姑息途径（n=1）
       无2周数据（n=12）
              未治疗（n=9）
              死亡（n=1）
              退出授权同意（n=1）
              对研究过程依从性差（n=1）
可获取的6周数据（n=71）
       无数据（n=16）
              未治疗（n=9）
              死亡（n=2）
              退出同意（n=3）
              对研究过程依从性差（n=1）
              没有给出原因（n=1）
可获取的12周数据（n=66）
       无12周数据（n=21）
              未治疗（n=9）
              搬迁（n=1）
              死亡（n=5）
              不耐受随访（n=1）
              退出授权同意（n=3）
              对研究过程依从性差（n=1）
              没有给出原因（n=1）
              无VFS数据（n=36）
       未治疗（n=9）
              病情严重不宜行VFS（n=3）
              搬迁无法回来接受VFS（n=2）
              患者拒绝行VFS（n=4）
              没有给出原因（n=2）
              死亡（n=9）
              没有进行SLT（n=1）
              退出授权同意（n=3）
              肺炎（n=1）
              对研究过程依从性差（n=1）
              试验点忘记记录VFS（n=1）
可获取的初级终点数据（n=56）
       无VFS数据（n=19）
              未治疗（n=12）
              不耐受VFS（n=1）
              无成功随机化分配即退出授权同意（n=1）
              仅1次随机化分配后退出授权同意（n=1）
              退出授权同意（n=1）
              死亡（n=1）
              VFS影像无法读取（n=1）
              患者有法定代理人（n=1）
       无2周数据（n=14）
              未治疗（n=12）
              退出授权同意（n=1）
              仅1次随机化分配后退出授权同意（n=1）
可获取的6周数据（n=58）
       无数据（n=17）
              未治疗（n=12）
              死亡（n=3）
              退出授权同意（n=1）
              仅1次随机化分配后退出授权同意（n=1）
可获取的12周数据（n=55）
       无12周数据（n=20）
              未治疗（n=12）
              搬迁（n=1）
              死亡（n=2）
              不耐受随访（n=2）
              退出授权同意（n=2）
              仅1次随机化退出授权同意（n=1）
       无VFS数据（n=31）
              未治疗（n=12）
              病情严重不宜行VFS（n=3）
              退出授权同意（n=2）
              搬迁或无法回来复查VFS（n=2）
              死亡（n=9）
              无成功随机化分配即退出授权同意（n=1）
              仅1次随机化分配后退出授权同意（n=1）
              运输或程序耗费较大（n=1）
随机入组（n=162）
多伦多床旁吞咽测试法进行确认）、处于清醒状态 [ 美国国立卫生
研究院卒中量表（National Institutes of Health Stroke Scale，
NIHSS）问题 1a 的评分为 0 或 1]、至少有一次（应用 VFS 评估）
PAS 评分≥ 3（见在线补充数据的描述）13，并且在卒中发病 42 d
内可以治疗。在入院后入组前，应用计算机断层扫描（computed 











Bundesamt für Strahlenschutz 管理机构不允许代理同意。试验




确定存在吞咽障碍（PAS ≥ 3）后，采用 VFS（见下文）作为
研究方法进行评估 14。研究人员将基线和后续数据输入一个商业数据
库（Rave, Medidata Solutions, Inc），这个数据库与一个随机化
的列表（Quantics Consulting, Ltd）相关联。对数据进行检查以
确定患者的资格，然后系统按照分配比例为 1:1，指派一个参与者进




实施 VFS。在每一个时间点（基线、第 2 周和第 12 周），给每个受
试者至多 6×5 ml 小团造影剂饮料（英国是 Omnipaque 300，法国
是 Visipaque 270 或 Accupaque 300），液体浓度（≈ 40% wt/
vol）。然后给受试者饮用 50 ml 造影剂，并记录其吞咽情况。
在基线时，3 项阳性才会使用小团造影剂饮料（即至少一次吞咽













图 1 本试验的患者入组情况 : 同意 195 例；采用 VFS 透视者 181 例；随机分配入组 162 例；拟治
疗 152 例；实施治疗 141 例；治疗患者中进行 2 周 VFS 评估 126 例；接受 3 次治疗并进行 2 周
VFS 评估 123 例；进行 12 周 VFS 评估 95 例。注：AE：负性事件；CIP：临床研究计划；Rx：
随机化；SLT：语言治疗；VFS：视频透视。




疗 3 d 9。在每个疗程中，将导管与控制基座相连，将电流频率调至 5 Hz，
然后逐渐由 1 mA 调高到可检测的阈值（患者开始意识到刺激），然
后调到所有患者的耐受电流强度水平（患者不能忍受更高的电流时）。
随机分配到 PES 治疗组的患者采取上述实施过程，使用治疗电流量













主要观察指标检测是在 2 周时用 VFS 方法评估造影剂误吸的 PAS
值 14。3 项测试研究中均在 2 周时应用 VFS 评估 12。作为次要观察指标，
在 12 周时应用 PAS 进行评分。
在第 2、第 6 和第 12 周出现的其他预先设定的次要指标包括：临
床吞咽障碍（DSRS9；参考在线补充数据）、依赖性 [ 改良 Rankin 量
表（modified Rankin Scale，mRS）15,16]、日常生活能力 / 障碍（Barthel
指数 17）、功能障碍（NIHSS18）、健康相关的生活质量 [ 欧洲生活质量 -5















计划招募 140 例患者以检测出 PAS 变化（所有可用丸饮剂引起吞咽的
平均值），处理组间从基线到 2 周的变化为 1.1 点（标准差为 1.8），
效能 90%，双边界值 5%，允许有 15% 患者随访的数据不全或丢失。




按照以下原则创建 4 个分析群：随机化，即所有人被分配到 PES
人数 随机入组 PES 治疗 假治疗
患者 162 162 87 75
年龄，岁 162 74.4（11.2） 74.0（9.9） 74.9（12.6）
性别，男性（%） 162 94（58.0） 48（55.2） 46（61.3）
种族（%） 162
    亚裔 15（9.3） 9（10.3） 6（8.0）
    黑种人 4（2.5） 0（0.0） 4（5.3）
    白种人 139（85.8） 74（85.1） 65（86.7）
    其他 4（2.5） 4（4.6） …
量表评分（/6） 153 4.0（1.1） 3.9（1.1） 4.1（1.2）
Barthel 指数（/100） 153 28.4（29.8） 32.4（31.7） 23.8（26.8）
卒中，既往卒中（%） 162 23（14.2） 15（17.2） 8（10.7）
影像可见（%） 161 42（26.1） 25（28.7） 17（23.0）
卒中类型（%） 161
    缺血性 / 正常 143（88.8） 77（89.5） 66（88.0）
    脑内出血性 17（10.6） 9（10.5） 8（10.7）
    无卒中 1（0.6） 0（0） 1（1.3）
CT 中病变侧（%） 158
    左侧 63（39.9） 33（38.4） 30（41.7）
    右侧 69（43.7） 36（41.9） 33（45.8）
    无病变 26（16.5） 17（19.8） 9（12.5）
症状（%） 157
    全前循环 41（26.1） 21（24.4） 20（28.2）
    部分前循环 69（43.9） 44（51.2） 25（35.2）
    腔隙性 46（29.3） 21（24.4） 25（35.2）
    后循环 1（0.6） 0（0.0） 1（1.4）
严重，NIHSS（/42） 152 9.9（6.4） 9.6（6.5） 10.2（6.2）
言语障碍，NIHSS（%） 152 55（36.2） 29（35.8） 26（36.6）
发病 - 随机入组天数（d） 162
    平均值（SD） 13.4（9.7） 12.6（9.5） 14.4（10.0）
    中位数 (IQR) 11（6~18） 10（5~17） 12（6~21）
DSRS（/12） 154 7.6（3.8） 8.0（3.9） 7.0（3.5）
TOR-BSST，失败（%） 162 158（97.5） 85（97.7） 73（97.3）
进食方式（%） 162
    经口，普食 10（6.2） 5（5.7） 5（6.7）
    经口，软食 45（27.8） 23（26.4） 22（29.3）
    经鼻饲 90（55.6） 52（59.8） 38（50.7）
    PEG 4（2.5） 3（3.4） 1（1.3）
    其他 13（8.0） 4（4.6） 9（12.0）
体重（kg） 153 71.9（16.4） 71.9（15.3） 72.0（17.6）
体质指数（kg/m2） 148 25.2（5.0） 25.7（4.8） 24.7（5.2）
臂中围（cm） 143 28.3（3.6） 28.2（3.7） 28.5（3.6）
白蛋白（g/l） 144 36（5.7） 36.4（5.8） 35.5（5.6）
胸部感染（%） 156 8（5.1） 3（3.6） 5（6.9）
渗透误吸评分（/8） 162 4.7（2.0） 4.7（2.1） 4.7（1.9）









基线和 2 周时的初级结果（PAS 值）；操作流程化，即随机分配的患
者接受所有 3 项治疗，并且计算所有患者的基线和 2 周时的 PAS 值。
应用多次线性回归方法，调整治疗中的 PAS 值至基线 PAS 值、
分 层 变 量（ 试 验 点 和 进 食 状 态）、 预 后 基 线 变 量（ 年 龄、 性 别、
NHISS），来对比分析各治疗组之间的吞咽状态。次级结果分析使
用 的 是： 多 次 线 性 回 归（ 针 对 连 续 性 数 据， 例 如 EQ-5D）、 有 序
logistic 回 归（ 有 序 分 类 数 据， 例 如 mRS）、 二 元 logistic 回 归
（二次分类数据，例如 PAS ≤ 3、严重负性事件、胸部感染）以及
Kaplan-Meier 和 Cox 回归模型。95% 的可信区间，P<0.05 被认为
差异有显著性。分析过程使用的是 SAS 软件（版本 9.3）。进行总结
的 meta 分析是基于咽部电刺激治疗吞咽障碍的组数据（Swallowing 
Treatment Using Pharyngeal Electrical Stimulation，STEPS）和





2012 年 4 月 -2014 年 9 月，选取 195 例患者进行试验；用 VFS
观察了 181 例患者；对 162 例患者分配治疗（随机人群）；对 152 例
患者尝试进行治疗（安全群体）；实际治疗 141 例患者（至少给予 1
个疗程的 PES 治疗或假治疗）；获得了 126 例患者的 2 周 VFS 结果（初
级结果群体）；获得 95 例患者的 12 周 VFS 结果（图 1）。进入试验
和随机分配入组的患者人数之间的差别包括：VFS 透视结果显示误吸
阴性者、导管插入失败者和治疗后 2 周无 VFS 结果的患者。162 例随
机分配入组的患者来自 5 个国家（丹麦、法国、德国、西班牙和英国，
见在线补充数据）的 20 个试验点招募而来；这其中 87 例患者被分配
到 PES 治疗组，75 例患者被分配到假治疗组（图 1）。101 例患者（62.3%）
招募自英国。随机分组的基线平衡性良好（表 1）: 平均年龄 74 岁（标
准差为 11），94 例为男性（58%），143 例患者曾有缺血性卒中（89%）。
从发生卒中到被随机分组的时间平均为 13（10）d。数据监测委员会
回顾了 3 次试验，每次都建议试验应继续进行。
得到至少 1 个疗程治疗的参与者 141 例，对于分配到 PES 治疗组
或假治疗组的依从性良好。有 15 例接受治疗的参与者没有 2 周的 VFS
结果，有 126 例接受治疗的参与者有 2 周的 VFS 结果，这两种情况
的基线情况并没有明显差异。随机分配到假治疗组的患者都没有接受
PES 治疗，所有接受插管并且随机分配到 PES 治疗组的患者均接受了
至少一个疗程治疗。PES 治疗组的平均治疗刺激电流是 14.5 mA，平
均处理时长是 9.8 min，平均治疗次数是 3.0（见在线补充数据表Ⅰ）。
然而目前水平恰当治疗的证据似乎存在：58% 的 PES 治疗患者的治疗
电流水平＜ 10.2 mA（从既往研究中选择的数值 12），治疗电流值水
平与阈值水平相同，或治疗电流值水平低于阈值水平。
在主要观察指标数据中，平均 PAS 的基线为 4.8（标准差为 2.0），
在 2 周时 2 组的 PAS 值均有所下降（表 2）。按照年龄、试验点、
NHISS、基础进食状态和 PAS 值进行调整，2 周的 PAS 差异并无显著
性，平均差异为 0.14（95% 可信区间，-0.37~0.64；P =0.60；表 2 和
图 2）；基线到 2 周 PAS 值的平均变化值在 2 组之间差异并无显著性：







食方式包括 12 周的造影剂误吸（PAS）、2 周及 12 周的临床吞咽障
碍情况（DSRS）和进食途径（表 3；在线补充数据表Ⅱ）。对于功能
性评价方法（mRS 和 Barthel 指数），支持 PES 治疗的明显趋势在第


















    PAS（/8） 4.8（2.0） 4.8（2.1） 4.7（1.9） … … … …
2 周时的初级结果
    所有丸剂平均值（/8） 3.6（2.0） 3.7（2.0） 3.6（1.9） 0.14（-0.37~0.64） 0.6 0.06（-0.62~0.74） 0.86
    从基线的变化值 -1.2（1.8） -1.2（1.8） -1.2（1.8） 0.14（-0.37~0.64） 0.6 0.00（-0.62~0.61） 1
    任何一次 PAS>3（%） 105（83.3） 60（85.7） 45（80.4） 1.22（0.29~5.15） 0.79 1.47（0.57~3.75） 0.42
12 周时的结果
    所有丸剂平均值（/8） 3.2（2.1） 3.3（2.2） 3.0（2.1） 0.29（-0.04~0.99） 0.41 0.24（-0.6~1.08） 0.57
    任何一次 PAS>3（%） 69（72.6） 36（70.6） 33（75.0） 0.62（0.20~1.90） 0.41 0.80（0.32~1.99） 0.63
重复测定
    平均值（/8）* … 4.1（2.3） 3.9（2.3） 0.51（-0.23~1.25） 0.18 0.19（-0.67~1.04） 0.67
注：所有患者都接受基线状态和 2 周的诊断性 VFS 检查，并且都接受至少 1 个疗程治疗。表中数据代表数值（%）、中位数（四分位数间距）或均值（标准差）。使用校正和
未校正的多元线性回归、有序 logistic 回归或二元 logistic 回归进行分析。CI：可信区间；MD：平均差；OR：比值比；PAS：渗透误吸评分；PES：咽部电刺激方法。
* 包括死亡：PAS=9。
表 2 分配入组治疗有效人群的 2 周时的 PAS 值
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者数量在 2 组之间差异无显著性：












从 STEPS 到 先 前 试 验 的 一 个
总 结 性 的 meta 分 析 中 9,11， 随 机





差 值 为 -0.94（95% 可 信 区 间，-




应 用 PAS 值 和 吞 咽 障 碍 严 重 程 度













的， 这 个 meta 分 析 是 对 DSRS 的
阳性总结 9,11,12，以及多发性硬化和
气管切开的卒中患者的阳性试验 21,22。







（PAS=4.8）的平均基础 PAS 值与既往 PES 治疗卒中试验相近（4.312；
见在线补充数据表Ⅴ），但是却低于一个关于多发性硬化的阳性试验
的数值（PAS=6.521）。有关联的是，在既往研究中随机进入假 PES 治
疗组的患者倾向于 PAS 和 DSRS 进展很小或没有总体的进展，但是本






图 2  在预先设定的亚组基线状态下，应用渗透误吸评分表示的治疗效果，采用校正的多次线性回归进行分析。注：MD：平均差；CI：可信区间；
DSRS：吞咽障碍严重程度评分；LACS：腔隙性循环综合征；NIHSS：美国国立卫生院卒中评分量表；PACS：部分前循环综合征；PAS：渗透
误吸评分；PES：咽部电刺激方法；TACS：全部前循环综合征。
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    DSRS（/12）* 133 5.1（3.8） 5.2（4.1） 4.9（3.6） 0.31（-0.56~1.18） 0.49 0.23（-1.07~1.54） 0.72
    NIHSS（/42）* 134 9.6（7.2） 9.0（7.4） 10.2（7.1） -0.05（-1.42~1.32） 0.94 -1.19（-3.64~1.26） 0.34
    mRS（/6）* 134 3.9（1.1） 3.7（1.2） 4.1（1.0） 0.53（0.23~1.22） 0.14 0.49（0.26~0.92） 0.028
    BI（/100）* 134 36.2（34.9） 41.3（37.2） 29.8（31.0） 1.57（-3.60~6.73） 0.55 11.45（-0.22~23.13） 0.055
    死亡（%） 141 2（1.4） 1（1.3） 1（1.6） … … 0.81（0.05~13.13） 0.88
12 周
    DSRS（/12）* 124 4.2（5.1） 4.4（5.2） 3.9（5.1） 1.01（-0.44~2.46） 0.17 0.58（-1.23~2.39） 0.53
    EQ-5DasHUS（/1）* 113 0.02（0.40） 0.08（0.41） -0.04（0.39） 0.13（0.00~0.27） 0.054 0.12（-0.03~0.27） 0.11
    EQ-VAS* 105 50.3（30.7） 51.6（30.1） 48.6（31.7） -4.17（-15.22~6.88） 0.46 3.03（-8.70~14.76） 0.61
处置情况（%） 0.66 (0.30~1.49) 0.32 0.63 (0.31~1.26) 0.19
    家 30（21.3） 20（25.6） 10（15.9） … … … …
    公共机构 93（66.0） 49（62.8） 44（69.8） … … … …
    死亡 18（12.8） 9（11.5） 9（14.3） … … … …
事件发生事件
    被排除（天） 141 28.2（22.8） 27.7（22.7） 28.7（23.0） -0.33（-7.79~7.12） 0.93 -0.97（-9.72~7.78） 0.83
    死亡（%） 141 18（12.8） 9（11.5） 9（14.3） 1.11（0.34~3.59） 0.86 0.79（0.32~2.00） 0.62
注：BI：Barthel 指数；DSRS：吞咽障碍严重程度等级评定；EQ-5D：欧洲生活质量 -5 维；EQ-VAS：欧洲生活质量可视模拟评分；HR：危险系数；HUS：健康利用状态；MD：平均差；mRS：
改良 Rankin 量表；NIHSS：美国国立卫生院卒中评分量表；OR：比值比；PES：咽部电刺激方法。
* 包括死亡：NHISS=43，DSRS=13，mRS=6，BI=-5，HUS=0。
表 3 分配入组的患者中至少接受 1 次治疗或假治疗的患者和可以被测量出结果的患者的临床和安全性结果











STEPS 中平均水平（平均治疗电流为 14.8 mA）低于以前卒中阳性试
验中所用的水平（16.8 mA12）。PES 治疗组中有 58% 的参与者，被
给予低于 10.2 mA（既往试验中标准差平均值为 -112）的治疗电流水
平或小于等于 0 mA 的阈值水平进行治疗，这样的刺激治疗量是不够的。
重要的是，已有研究表明，刺激量级与误吸的进展有关 8。调查人员关
心患者的潜在伤害似乎可以解释这个情况，尽管研究没有显示关于有





10~20 min（而 PES 治疗组患者的治疗时长为 30 min 以上）。这些
对于 STEPS 结果可能的解释为今后 PES 治疗试验和其他仪器试验的
设计和调查人员的培训提供了线索。






入试验，162 例患者被随机分配入组，但是仅有 126 例患者接受了至









实际治疗时并不存在。然而，第 2 周、第 6 周和第 12 周对临床结果的
评定是由训练有素的人员进行评估的，这些人员不知道治疗分配的情
况，也不参与所招募患者的住院护理。并且，VFS 影像是由同样被设盲、
不知道随机分组的放射科医生或语言治疗师来进行判定的。
综上所述，本研究发现 PES 治疗不能减少放射性吸入或临床吞咽
障碍。这个结果与之前一个关于 PES 治疗卒中后吞咽障碍的小样本试
验 meta 分析不同，之前的试验结果可能有其他混杂因素存在，这些因
素包括招募的患者是轻度的吞咽障碍、PES 治疗剂量不足和可能给予
对照患者治疗量刺激。鉴于这其中的差异以及小样本试验高估治疗效
果的潜在风险，关于伴有严重吞咽障碍或要求重症监护（包括辅助通气）
的卒中患者的进一步的研究已在计划之中。
